Why orphan drugs are a key part of pharma’s future?

Back in the 1980's when the Orphan Drug Act was created, legislators, government agencies and even industry weren't expecting that it would create a multi-billion dollar market where companies now fight fiercely for a share in this segment. It's also understood that the timing of the Act was very fortuitous as it was closely aligned with the beginning of US' …

Europe’s reaction to CAVOMP’s harmonization in the orphan drugs space

There are conflicting opinions about CAVOMP and how far it will go with harmonizing reimbursement policies among the 27 countries in the EU. We need to remember that sovereignty issues to consider as well. Governments, the EMA, industry, payers and patients, all feel that more collaboration is necessary in order to align everyone's interests. It may also be necessary to …

Pharmaceutical Pricing and Reimbursement in Europe

GBI Research, the leading business intelligence provider, has released its latest research "Pharmaceutical Pricing and Reimbursement in Europe – Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies". It provides a comprehensive overview of the healthcare systems as well as pricing and reimbursement processes in 12 European nations with a detailed analysis of …